Compares CM336 with standard treatment in relapsed multiple myeloma
Tests CM336 against standard treatment in adults with returning myeloma.
Plain-language title generated from the registry record
Registry title: Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 3
Where in China
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Keymed Biosciences Co.Ltd
- Trial code
- NCT07181239
- Record updated
- 18 September 2025
- Original description
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.Read full original descriptionShow less
A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Inclusion: The subjects voluntarily sign the informed consent form (ICF) and agree to abide by the provisions of this protocol; Age ≥ 18 years old, gender is not limited; Eastern Cooperative Oncology Group performance status score (ECOG) 0-2 points; Patients with relapsed or refractory multiple myeloma who have received at least two lines of anti-myeloma treatment previously, and must include at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-Cluster of Differentiation 38(CD38) monoclonal antibody; The subject has evidence of disease progression or has not achieved remission after the last line of treatment, as determined by the investigator based on the International Myeloma Working Group (2016) criteria; The subject has measurable disease at the screening period, meeting at least one of the following criteria:; Serum M protein ≥ 5 g/L; Urinary M protein ≥ 200 mg/24 h; Serum free light chain (sFLC) ≥ 100 mg/L and abnormal κ/ λ ratio.
Exclusion: Previous receipt of any treatment targeting B-cell maturation antigen (BCMA); Those who are intolerant to dexamethasone will be excluded; Within 3 months prior to the first administration, they have received chimeric antigen receptor T cells (CAR-T) /chimeric antigen receptor Nature killer cell (CAR-NK) therapy; Within 3 months prior to the first administration, they have received autologous stem cell transplantation; within 6 months prior to the first administration, they have received allogeneic stem cell transplantation (for subjects who have received allogeneic transplantation, they must have discontinued all immunosuppressants for ≥ 6 weeks and have no signs of graft-versus-host disease before being eligible for enrollment).